Latest News

Journal Articles

0Adoption of trastuzumab for breast cancer in four emerging countries in the use of HTA: a case study

This case study aims to describe the HTA processes and methods used in the adoption of an essential cancer drug such as trastuzumab in a selection of emerging countries in the use of HTA from the central, eastern and south eastern Europe (CESEE) and Latin America and the Caribbean (LAC) regions. The ultimate goal of this paper is to draw useful lessons for settings with evolving or newly-established HTA systems.

Brain and neurologic

Could altering a toxic drug make it safe for glioblastoma treatment?

Elevated protein marker in neuroblastoma may lead to prognostic test

Enzyme may increase metastatic potential in medulloblastoma


Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives

Contrast-enhanced spectral mammography can provide answers sooner

Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics


ESMO16: Trial results reported for nintedanib for metastatic colorectal cancer

Checkpoint inhibition for colorectal cancer: progress and possibilities

Colorectal cancer stem cells could be targeted with novel Wnt inhibitor


The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer

Targeting PI3K isoform shows therapeutic promise in pancreatic neuroendocrine tumors

New treatment hopes for patients with inoperable neuroendocrine cancers?


Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization

Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe?

RSP6KB1–VMP1 fused gene offers new disease insight in esophageal cancer


Metabolism genes may embody marker of response to nivolumab in renal cell carcinoma

Systemic therapy for metastatic bladder cancer in 2016 and beyond

New research could help personalize treatment in early bladder cancer


Researchers identify genes involved in aggressive ovarian and endometrial cancers

ESMO16: Niraparib improves progression-free survival in recurrent ovarian cancer

Sticky nanoparticles for a tricky issue: improving drug delivery for gynecological cancer

Head and neck

Most detailed image of head and neck cancer stem cells to date revealed

Induction chemotherapy for head and neck cancer: is there still a role?

US FDA grant approval of pembrolizumab for advanced head & neck cancer


Novel microarray-based method for examining single leukemia cells could improve treatment

3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

Promising results demonstrated for CAR-T therapy in advanced non-Hodgkin lymphoma patients


Potential role of intensity-modulated radiotherapy demonstrated in new case reports

ESMO16: Pembrolizumab shows therapeutic potential in non-small-cell lung cancer

ESMO16: Atezolizumab significantly improves lung cancer survival vs standard chemotherapy in Phase III trial


Prolonging the survival of advanced pancreatic cancer patients with a novel immunotherapy drug

Pancreatic cancer screening using a multiplatform human serum metabolomics system

Unique pancreatic cancer cell survival mechanism uncovered


Blood biomarkers may highlight the presence of drug-resistant tumor cells in prostate cancer

ASTRO16 news round-up

First results from ProtecT trial in prostate cancer published

Rare tumors

Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Should clinical trials be approached differently for rare cancers?

Novel targets for natural killer/T-cell lymphoma immunotherapy


40 years in melanoma research: an interview with Meenhard Herlyn about his career in research and the outlook for the field

Melanoma brain metastases: promising results for immune and targeted therapies combined with radiosurgery

Role of rare germline copy number variation in melanoma-prone patients